Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.
Actym Therapeutics is a biotech company using engineered bacteria to deliver cancer immunotherapies. Its website says the bacterial delivery platform is in a phase 1 clinical trial for solid tumors.
Actym Therapeutics, Inc. was founded in 2017 by Amit Kumar, Christopher Thanos, Laura Hix Glickman.
Source: Crunchbase.
Traffic estimates from Semrush, latest month.
Actym Therapeutics, Inc. may be growing as it has expanded its Series A funding round, which is a strong indicator of investor confidence and financial backing for its research and development efforts. The expansion of the funding round suggests that the company has access to more capital to advance its immuno-oncology therapies. Additionally, the focus on engineering bacteria to combat cancer indicates ongoing product development, which is critical for growth in the biotechnology and oncology sectors. The company's activities align with the industry's trend of seeking innovative treatments for cancer, which may further support its growth trajectory.
Source: Crunchbase growth insight.
“Actym Therapeutics is deploying its biologically brilliant bacteria drug delivery platform to treat cancer with powerful immunotherapies. We are advancing our bacteria delivery system for cancer immunotherapy in a phase 1 clinical trial for solid tumors.” actymthera.com
Source: company website, checked 2026-10-26.
Search verified work emails and direct dials for people at actymthera.com.
Or explore the full B2B database and filter by biotechnology companies.